D Lawrence Wickerham

Summary

Affiliation: National Surgical Adjuvant Breast and Bowel Project
Country: USA

Publications

  1. ncbi request reprint The use of tamoxifen and raloxifene for the prevention of breast cancer
    D Lawrence Wickerham
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Allegheny Center, Pittsburgh, PA 15212, USA
    Recent Results Cancer Res 181:113-9. 2009
  2. pmc The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project
    D Lawrence Wickerham
    NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Semin Oncol 35:522-9. 2008
  3. ncbi request reprint An update on breast cancer prevention trials
    D L Wickerham
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, USA
    Int J Gynecol Cancer 16:498-501. 2006
  4. pmc Breast cancer chemoprevention: progress and controversy
    D Lawrence Wickerham
    National Surgical Adjuvant Breast and Bowel Project NSABP, Four Allegheny Center 5th Floor, Pittsburgh, PA 15212, USA
    Surg Oncol Clin N Am 19:463-73. 2010
  5. ncbi request reprint Tamoxifen--an update on current data and where it can now be used
    Lawrence Wickerham
    National Surgical Adjuvant Breast and Bowel Project, Operations Center, Pittsburgh, PA, USA
    Breast Cancer Res Treat 75:S7-12; discussion S33-5. 2002
  6. ncbi request reprint The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project
    D Lawrence Wickerham
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania 15212, USA
    World J Surg 30:1138-46. 2006
  7. pmc Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer
    Victor G Vogel
    NSABP, Pittsburgh, PA 15212, USA
    Cancer Prev Res (Phila) 3:696-706. 2010
  8. ncbi request reprint Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
  9. pmc Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Departmentof Biostatistics, Graduate School of Public Health, University of Pittsburgh, USA
    J Clin Oncol 28:1677-83. 2010
  10. doi request reprint Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR)
    Reena S Cecchini
    NSABP Biostatistical Center, One Sterling Plaza, Pittsburgh, PA 15213, USA
    Cancer Prev Res (Phila) 5:1321-9. 2012

Detail Information

Publications46

  1. ncbi request reprint The use of tamoxifen and raloxifene for the prevention of breast cancer
    D Lawrence Wickerham
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Allegheny Center, Pittsburgh, PA 15212, USA
    Recent Results Cancer Res 181:113-9. 2009
    ..51 vs 2.11 per 1,000; RR, 1.40; 95% CI, 0.98-2.00). There were 36 cases of uterine cancer with tamoxifen and 23 cases with raloxifene (RR, 0.63; 95% CI, 0.35-1.08)...
  2. pmc The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project
    D Lawrence Wickerham
    NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Semin Oncol 35:522-9. 2008
    ....
  3. ncbi request reprint An update on breast cancer prevention trials
    D L Wickerham
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, USA
    Int J Gynecol Cancer 16:498-501. 2006
    ..In this paper, we review the most prominent studies, all of which are either under way or in follow-up...
  4. pmc Breast cancer chemoprevention: progress and controversy
    D Lawrence Wickerham
    National Surgical Adjuvant Breast and Bowel Project NSABP, Four Allegheny Center 5th Floor, Pittsburgh, PA 15212, USA
    Surg Oncol Clin N Am 19:463-73. 2010
    ..The agents of established value are important options for women today, and efforts are under way to identify additional more effective therapies...
  5. ncbi request reprint Tamoxifen--an update on current data and where it can now be used
    Lawrence Wickerham
    National Surgical Adjuvant Breast and Bowel Project, Operations Center, Pittsburgh, PA, USA
    Breast Cancer Res Treat 75:S7-12; discussion S33-5. 2002
    ..In trials performed by the Swedish Breast Cancer Co-operative Group and the NSABP, the optimal duration of adjuvant tamoxifen therapy appears to be 5 years, although this is equivocal and not yet conclusively defined...
  6. ncbi request reprint The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project
    D Lawrence Wickerham
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania 15212, USA
    World J Surg 30:1138-46. 2006
    ....
  7. pmc Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer
    Victor G Vogel
    NSABP, Pittsburgh, PA 15212, USA
    Cancer Prev Res (Phila) 3:696-706. 2010
    ..These results have important public health implications and clarify that both raloxifene and tamoxifen are good preventive choices for postmenopausal women with elevated risk for breast cancer...
  8. ncbi request reprint Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
    ..The relationship between the RS and chemotherapy benefit is not known...
  9. pmc Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Departmentof Biostatistics, Graduate School of Public Health, University of Pittsburgh, USA
    J Clin Oncol 28:1677-83. 2010
    ....
  10. doi request reprint Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR)
    Reena S Cecchini
    NSABP Biostatistical Center, One Sterling Plaza, Pittsburgh, PA 15213, USA
    Cancer Prev Res (Phila) 5:1321-9. 2012
    ....
  11. doi request reprint Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Gong Tang
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, and Pathology Division, Pittsburgh, PA, USA
    Breast Cancer Res Treat 127:133-42. 2011
    ..219) or DFS (P = 0.099). Prognostic estimates can be optimized by combining RS and clinicopathologic information instead of simply combining RS and Adjuvant!. RS should be used for estimating relative chemotherapy benefit...
  12. doi request reprint Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials
    Reena S Cecchini
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Center, One Sterling Plaza, 201 N Craig St, Suite 350, Pittsburgh, PA 15213, USA
    Cancer Prev Res (Phila) 5:583-92. 2012
    ....
  13. ncbi request reprint Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
    JAMA 295:2727-41. 2006
    ..Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis...
  14. doi request reprint Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)
    Carolyn D Runowicz
    National Surgical Adjuvant Breast and Bowel Project, National Cancer Institute, Pittsburgh, PA, USA
    Am J Obstet Gynecol 205:535.e1-5. 2011
    ..This study reports the gynecologic conditions in postmenopausal women (intact uterus on enrollment) in the National Surgical Adjuvant Breast and Bowel Project (NSABP) study of tamoxifen and raloxifene (STAR)/P-2 trial...
  15. pmc Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24
    D Craig Allred
    National Surgical Adjuvant Breast and Bowel Project, Washington University School of Medicine, Department of Pathology and Immunology, 660 Euclid Campus Box 8118, St Louis, MO 63110, USA
    J Clin Oncol 30:1268-73. 2012
    ..Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen...
  16. ncbi request reprint Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project, Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 23:3686-96. 2005
    ....
  17. ncbi request reprint Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Bernard Fisher
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Natl Cancer Inst 97:1652-62. 2005
    ..Side effects of varying clinical significance were observed. The trial was unblinded because of the positive results, and follow-up continued. This report updates our initial findings...
  18. ncbi request reprint National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ
    Victor G Vogel
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 3180, USA
    Clin Cancer Res 9:495S-501S. 2003
    ..Outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease. Enrollment will begin in early 2003...
  19. ncbi request reprint Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Harry D Bear
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Clin Oncol 24:2019-27. 2006
    ..This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS)...
  20. pmc Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer
    Stewart J Anderson
    Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
    J Clin Oncol 27:2466-73. 2009
    ..Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has not been adequately characterized in patients with lymph node-negative disease...
  21. pmc Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer
    Chungyeul Kim
    National Surgical Adjuvant Breast and Bowel Project, Division of Pathology, 1307 Federal St, Pittsburgh, PA 15212, USA
    J Clin Oncol 29:4160-7. 2011
    ..We used gene expression profiling and ER protein assays to help elucidate molecular mechanism(s) responsible for tamoxifen resistance in breast tumors...
  22. ncbi request reprint Lower-category benign breast disease and the risk of invasive breast cancer
    Jiping Wang
    Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 96:616-20. 2004
    ..This report evaluates the risk of breast cancer associated with this lower-category BBD (LC-BBD)...
  23. ncbi request reprint Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial
    Neil Abramson
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
    J Natl Cancer Inst 98:904-10. 2006
    ..However, the involvement of hypercoagulability factors in this association is unclear...
  24. ncbi request reprint Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    JAMA 295:2742-51. 2006
    ..Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown...
  25. ncbi request reprint A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  26. ncbi request reprint Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
    J Clin Oncol 20:4141-9. 2002
    ....
  27. doi request reprint Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials
    Victor G Vogel
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    J Natl Cancer Inst Monogr 2010:181-6. 2010
    ..51 per 1000 women assigned to tamoxifen and 2.11 per 1000 women assigned to raloxifene (risk ratio, 1.40; 95% confidence interval = 0.98 to 2.00)...
  28. pmc Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, University of Pittsburgh, PA, USA
    Cancer Prev Res (Phila) 4:1393-400. 2011
    ..001; OR = 1.5 high vs. low) predicted adequate adherence at 36 months. There were no significant associations with obesity or physical activity. Alcohol use and smoking might indicate a need for greater adherence support...
  29. ncbi request reprint Pathologic variables predictive of breast events in patients with ductal carcinoma in situ
    Edwin R Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    Am J Clin Pathol 128:86-91. 2007
    ..The similar predictive role of comedo necrosis in this study and that reported previously from NSABP B-17 (total of 2,079 patients) strongly supports its role as a simple high-risk predictor for ipsilateral breast tumor recurrences...
  30. ncbi request reprint The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial
    Victor G Vogel
    The National Surgical Adjuvant Breast and Bowel Project, NSABP Foundation Inc, Pittsburgh, PA, USA
    Clin Breast Cancer 3:153-9. 2002
    ..0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast..
  31. ncbi request reprint Is tamoxifen a risk factor for retinal vaso-occlusive disease?
    Michael B Gorin
    Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Retina 25:523-6. 2005
  32. ncbi request reprint Tamoxifen's impact as a preventive agent in clinical practice and an update on the STAR trial
    D Lawrence Wickerham
    NSABP Operations Center, East Commons Professional Building, Four Allegheny Center, 5th Floor, Pittsburgh, PA 15212, USA
    Recent Results Cancer Res 163:87-95; discussion 264-6. 2003
    ..Its second prevention study, the STAR trial, is currently under way...
  33. ncbi request reprint Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    J Clin Oncol 23:2694-702. 2005
    ..Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated with neoadjuvant chemotherapy...
  34. ncbi request reprint Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience
    Soonmyung Paik
    National Surgical Adjuvant Breast and Bowel Project NSABP Operation Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 94:852-4. 2002
    ..This report provides a snapshot of the quality of HER2 assays performed in laboratories nationwide...
  35. ncbi request reprint Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
    Breast Cancer Res Treat 97:245-54. 2006
    ..Both obesity and estrogen receptor negative (ER-) tumors are more prevalent in black women than in whites in North America. We evaluated obesity and race in relation to outcomes in women with ER-breast cancer...
  36. ncbi request reprint Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1)
    Mary S Beattie
    Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, USA
    J Natl Cancer Inst 98:110-5. 2006
    ..The purpose of this study was to determine whether sex hormone levels were associated with breast cancer risk and with response to tamoxifen in a high-risk population...
  37. ncbi request reprint Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial
    Eva Chalas
    Department of Obstetrics, Gynecology and Reproductive Medicine, Stony Brook University, State University of New York, Stony Brook, NY
    Am J Obstet Gynecol 192:1230-7; discussion 1237-9. 2005
    ..This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project...
  38. ncbi request reprint The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Harry D Bear
    Virginia Commonwealth University, Medical College of Virginia School of Medicine, Richmond, VA, USA
    J Clin Oncol 21:4165-74. 2003
    ....
  39. ncbi request reprint Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    Victor G Vogel
    J Natl Cancer Inst 94:1504. 2002
  40. doi request reprint Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial
    Eleftherios P Mamounas
    Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
    J Clin Oncol 26:1965-71. 2008
    ....
  41. ncbi request reprint Effects of tamoxifen on benign breast disease in women at high risk for breast cancer
    Elizabeth Tan-Chiu
    Cancer Research Network, 350 84th Avenue, Suite 305, Plantation, FL 33324, USA
    J Natl Cancer Inst 95:302-7. 2003
    ..We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women...
  42. ncbi request reprint Prevention of hormone-related cancers: breast cancer
    Barbara K Dunn
    National Cancer Institute, 6130 Executive Blvd, Room 2046, Bethesda, MD 20892, USA
    J Clin Oncol 23:357-67. 2005
    ....
  43. ncbi request reprint Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen
    Worta McCaskill-Stevens
    CORE Investigators National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, EPN 2014, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:1762-9. 2004
    ..Information about breast cancer treatment and prevention in African American women is scant, and recommendations for therapy from clinical trials for breast cancer are based primarily on data obtained from white women...
  44. ncbi request reprint Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer
    Sandra M Swain
    National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 96:516-23. 2004
    ....
  45. ncbi request reprint Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial
    Mary Cushman
    Department of Medicine, University of Vermont, Burlington, VT, USA
    Br J Haematol 120:109-16. 2003
    ..Reductions of antithrombin and protein S, but not protein C or APC resistance, might relate to the increased risk of venous thrombosis associated with tamoxifen treatment...
  46. ncbi request reprint Association of tamoxifen and uterine sarcoma
    D Lawrence Wickerham
    J Clin Oncol 20:2758-60. 2002